Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Completed 2Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1

Conditions

Higher-risk Myelodysplastic Syndrome 1

Interventions

Capecitabine 25Oxaliplatin 24Paclitaxel 23Gemcitabine 21Cisplatin 21Fluorouracil 20Carboplatin 18Drug Therapy 17Docetaxel 17pembrolizumab 15Leucovorin 15Irinotecan 15Radiotherapy 12tislelizumab 11Injections 10Radiation 9Pemetrexed 9Magnetic Resonance Spectroscopy 9Bevacizumab 9toripalimab 8Cetuximab 8Surgical Procedures, Operative 7Specimen Handling 7Radiotherapy, Intensity-Modulated 7Azacitidine 7venetoclax 6sintilimab 6atezolizumab 6Topotecan 6Cyclophosphamide 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Not yet recruiting × luspatercept × Clear all
NCT06927232 2025-04-15

AZA+Lus VS AZA Monotherapy in HR-MDS

Peking Union Medical College Hospital

Phase 3 Not yet recruiting
86 enrolled
Myeloid

Higher-risk Myelodysplastic Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡